SCHEMBL23705341

SCHEMBL23705341

OC1(c2cccc(Br)c2)CC2(COC2)C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 2/20 0.43
SLC6A4 P31645 2/20 0.43
SLC6A3 Q01959 2/20 0.43
CHRNA1 P02708 1/20 0.43
CHRNG P07510 1/20 0.43
CHRNB1 P11230 1/20 0.43
CHRNB2 P17787 1/20 0.43
CHRNB4 P30926 1/20 0.43
CHRNA3 P32297 1/20 0.43
CHRNA4 P43681 1/20 0.43
CHRND Q07001 1/20 0.43
HCAR3 P49019 1/20 0.35
HCAR2 Q8TDS4 1/20 0.35
NR4A2 P43354 1/20 0.31
SCD O00767 1/20 0.31
SCD5 Q86SK9 1/20 0.31
ALDH1A1 P00352 3/20 0.31
MAPK1 P28482 1/20 0.31
TP53 P04637 1/20 0.30
GAA P10253 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15272219 0.86 CHRNA1 (0.48) SLC6A2SLC6A4SLC6A3CHRNA1CHRNG
SCHEMBL23704829 0.80 CHRNA1 (0.38) SLC6A2SLC6A4SLC6A3CHRNA1CHRNG
SCHEMBL16203267 0.77 CHRNA1 (0.43) SLC6A2SLC6A4SLC6A3CHRNA1CHRNG
SCHEMBL23232243 0.76 CHRNA1 (0.44) SLC6A2SLC6A4SLC6A3CHRNA1CHRNG
SCHEMBL30820875 0.76 CHRNA1 (0.44) SLC6A2SLC6A4SLC6A3CHRNA1CHRNG
SCHEMBL932071 0.76 CHRNA1 (0.42) SLC6A2SLC6A4SLC6A3CHRNA1CHRNG
SCHEMBL23714901 0.75 SLC6A2 (0.44) SLC6A2SLC6A4SLC6A3CHRNA1CHRNG
SCHEMBL31274721 0.74 MEN1 (0.38) SLC6A2SLC6A4SLC6A3CHRNA1CHRNG
SCHEMBL31274950 0.74 CHRNA1 (0.37) SLC6A2SLC6A4SLC6A3CHRNA1CHRNG
SCHEMBL4882640 0.73 CHRNB2 (0.54) SLC6A2SLC6A4SLC6A3CHRNA1CHRNG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
EP-4096657-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2022-12-07 EP disclosed
WO-2021155316-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 WO disclosed
WO-2021155316-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230149414-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB SLC6A2 2837/4885SLC6A4 3358/4885SLC6A3 2779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.